Global Acromegaly Treatment Market Report and Forecast 2023-2031

Global Acromegaly Treatment Market Report and Forecast 2023-2031


Global Acromegaly Treatment Market Outlook


The global acromegaly treatment market size attained a value of USD 1.61 billion in 2022. The market is likely to witness further growth at a CAGR of 7.65% during the forecast period of 2023-2031 to attain a value of approximately USD 3.12 billion by 2031. The growth of the market can be attributed to the rising awareness about the disorder among healthcare professionals and patients.

Acromegaly: Introduction and Epidemiology

Acromegaly is a rare hormonal disorder that occurs due to the overproduction of growth hormone (GH) by the pituitary gland. The prevalence of acromegaly varies across different regions of the world, with an estimated global prevalence of 60 cases per million population.

Acromegaly typically affects adults between the ages of 30 and 50, although it can occur at any age. The disorder affects both men and women equally. However, some studies have suggested a slightly higher prevalence in women.

The prevalence of acromegaly is highest in certain regions of the world, such as Southern Europe and Latin America, where it is estimated to be as high as 100-130 cases per million population. In contrast, the prevalence is lower in North America and Asia, where it is estimated to be around 40-60 cases per million population.

There are no known lifestyle habits that increase the risk of developing acromegaly. However, certain medical conditions such as multiple endocrine neoplasia type 1 (MEN1) and Carney complex can increase the risk of developing the disorder.

In terms of prognosis, acromegaly can lead to significant morbidity and mortality if left untreated. The most common complications of acromegaly include cardiovascular disease, diabetes mellitus, sleep apnea, and osteoarthritis. However, with appropriate treatment, the long-term outlook for individuals with acromegaly is generally favourable.

In conclusion, acromegaly is a rare hormonal disorder that predominantly affects adults between the ages of 30 and 50. The prevalence of the disorder varies across different regions of the world, with higher prevalence rates in certain regions of Southern Europe and Latin America.

Global Acromegaly Treatment Market Segmentations


Market Breakup by Diagnosis Type
  • GH and IGF-I Measurement
  • Growth Hormone Suppression Test
  • Imaging
  • Spine x-ray
  • MRI of the brain, including the pituitary gland
  • Echocardiogram
  • Colonoscopy
  • Others
Market Breakup by Treatment Type
  • Medication
  • Somatostatin analogues
  • Dopamine agonists
  • Growth hormone antagonist
  • Others
  • Radiation Therapy
  • Surgery
  • Others
Market Breakup by Diseases Type
  • Ectopic Acromegaly
  • Acromegaly Due to Growth Hormone
Market Breakup by Route of Administration
  • Oral
  • Parentals
  • Others
Market Breakup by Treatment Centres
  • Hospitals
  • Specialty Clinics
  • Homecare Settings
  • Rehabilitation Centers
  • Others
Market Breakup by Treatment Channel
  • Public
  • Private
Market Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others
Market Breakup by Region

North America
  • United States of America
  • Canada
Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Global Acromegaly Treatment Market Scenario


The global market for acromegaly treatment is expected to grow significantly in the coming years. The market is primarily driven by the increasing prevalence of the disorder, the rising awareness about the disorder among healthcare professionals and patients, and the development of new and innovative treatment options.

Somatostatin analogues are the most commonly used drugs for the treatment of acromegaly and are expected to continue to dominate the market during the forecast period. However, GH receptor antagonists and dopamine agonists are expected to gain traction in the coming years due to their improved efficacy and safety profiles.

Geographically, the market is expected to experience significant growth in North America and Europe due to the high prevalence of acromegaly in these regions and the presence of well-established healthcare infrastructure. However, the Asia Pacific region is expected to witness the highest growth rate due to the increasing prevalence of the disorder and a growing demand for effective treatment options.

Key Players in the Global Acromegaly Treatment Market

The report gives an in-depth analysis of the key players involved in the global acromegaly market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Pfizer Inc.
  • GlaxoSmithKline plc.
  • Novartis AG
  • Merck & Co., Inc.
  • Allergan
  • AstraZeneca
  • Johnson & Johnson Private Limited
  • Hikma Pharmaceuticals PLC.
  • Bristol-Myers Squibb Company
  • Bayer AG
  • Boehringer Ingelheim International GmbH.
  • Dr. Reddy's Laboratories Ltd.
  • Gilead Sciences, Inc.
  • Eli Lilly and Company
  • AbbVie Inc.
  • Lupin


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Acromegaly Diseases Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Acromegaly Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Acromegaly Epidemiology (2016-2031)
5.3 Europe Acromegaly Epidemiology (2016-2031)
5.4 Asia-Pacific Acromegaly Epidemiology (2016-2031)
5.5 Latin America Acromegaly Epidemiology (2016-2031)
5.6 Middle East & Africa Acromegaly Epidemiology (2016-2031)
6 Global Acromegaly Treatment Market Overview
6.1 Global Acromegaly Treatment Market Historical Value (2016-2022)
6.2 Global Acromegaly Treatment Market Forecast Value (2023-2031)
7 Global Acromegaly Treatment Market Landscape
7.1 Acromegaly Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Cardiovascular Drugs Product Landscape
7.2.1 Analysis by Diagnosis Type
7.2.2 Analysis by Drug Type
7.2.3 Analysis by Route of Administration
7.2.4 Analysis by End User
7.2.5 Analysis by Distribution Channel
8 Acromegaly Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Acromegaly Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Acromegaly Treatment Market Segmentation
11.1 Global Acromegaly Treatment Market by Diagnosis Type
11.1.1 Market Overview
11.1.2 GH and IGF-I Measurement
11.1.3 Growth Hormone Suppression Test
11.1.4 Imaging
11.1.4.1 Spine x-ray
11.1.4.2 MRI of the brain, including the pituitary gland
11.1.4.3 Echocardiogram
11.1.4.4 Colonoscopy
11.1.4.5 Others
11.1.5 Others
11.2 Global Acromegaly Treatment Market by Treatment Type
11.2.1 Market Overview
11.2.2 Medication
11.2.2.1 Somatostatin analogues
11.2.2.2 Dopamine agonists
11.2.2.3 Growth hormone antagonist
11.2.2.4 Others
11.2.3 Radiation Therapy
11.2.4 Surgery
11.2.5 Others
11.3 Global Acromegaly Treatment Market by Diseases Type
11.3.1 Ectopic Acromegaly
11.3.2 Acromegaly Due to Growth Hormone
11.4 Global Acromegaly Treatment Market by Route of Administration
11.4.1 Market Overview
11.4.2 Oral
11.4.3 Parentals
11.4.4 Others
11.5 Global Acromegaly Treatment Market by Treatment Centers
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Specialty Clinics
11.5.4 Homecare Settings
11.5.5 Rehabilitation Centers
11.5.6 Others
11.6 Global Acromegaly Treatment Market by Treatment Channel
11.6.1 Market Overview
11.6.2 Public
11.6.3 Private
11.7 Global Acromegaly Treatment Market by Distribution Channel
11.7.1 Market Overview
11.7.2 Hospital Pharmacy
11.7.3 Retail Pharmacy
11.7.4 Online Pharmacy
11.7.5 Others
11.8 Global Acromegaly Treatment Market by Region
11.8.1 Market Overview
11.8.2 North America
11.8.3 Europe
11.8.4 Asia Pacific
11.8.5 Latin America
11.8.6 Middle East and Africa
12 North America Acromegaly Treatment Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Acromegaly Treatment Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Acromegaly Treatment Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Acromegaly Treatment Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Acromegaly Treatment Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 F. Hoffmann-La Roche Ltd.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Mylan N.V.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Teva Pharmaceutical Industries Ltd.
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Sanofi
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Pfizer Inc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 GlaxoSmithKline plc.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Novartis AG
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Merck & Co., Inc.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Allergan
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 AstraZeneca
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Johnson & Johnson Private Limited
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Hikma Pharmaceuticals PLC.
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 Bristol-Myers Squibb Company
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
23.14 Bayer AG
23.14.1 Financial Analysis
23.14.2 Product Portfolio
23.14.3 Demographic Reach and Achievements
23.14.4 Mergers and Acquisitions
23.14.5 Certifications
23.15 Boehringer Ingelheim International GmbH.
23.15.1 Financial Analysis
23.15.2 Product Portfolio
23.15.3 Demographic Reach and Achievements
23.15.4 Mergers and Acquisitions
23.15.5 Certifications
23.16 Dr. Reddy's Laboratories Ltd.
23.16.1 Financial Analysis
23.16.2 Product Portfolio
23.16.3 Demographic Reach and Achievements
23.16.4 Mergers and Acquisitions
23.16.5 Certifications
23.17 Gilead Sciences, Inc.
23.17.1 Financial Analysis
23.17.2 Product Portfolio
23.17.3 Demographic Reach and Achievements
23.17.4 Mergers and Acquisitions
23.17.5 Certifications
23.18 Eli Lilly and Company
23.18.1 Financial Analysis
23.18.2 Product Portfolio
23.18.3 Demographic Reach and Achievements
23.18.4 Mergers and Acquisitions
23.18.5 Certifications
23.19 AbbVie Inc.
23.19.1 Financial Analysis
23.19.2 Product Portfolio
23.19.3 Demographic Reach and Achievements
23.19.4 Mergers and Acquisitions
23.19.5 Certifications
23.20 Lupin
23.20.1 Financial Analysis
23.20.2 Product Portfolio
23.20.3 Demographic Reach and Achievements
23.20.4 Mergers and Acquisitions
23.20.5 Certifications
24 Acromegaly Treatment Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings